THE SKYEHUB MODEL

An innovative model combining :

• A land and real estate offer
• The building of tailor-made and dedicated manufacturing facilities
• Backing to the Skyepharma’s Quality system
• Provision of industrial services (maintenance, etc.)
• Appropriate industrial and regulatory environment (cGMP, ISO, FDA, etc.)

OBJECTIVES

• Complement the industrial bioproduction capacity in France
• Adapt this capacity to tomorrow’s technology needs 
• Facilitate and speed-up the emergence and the success of industrial start-ups and innovative SMEs
• Make France an European leader in pharmaceutical bioproduction, and thus strengthen its attractiveness and secure its independence in terms of supply
• Contribution to the structuring and development of the bioproduction ecosystem

MAIN ADVANTAGES AND DIFFERENCIATORS

• An alternative and complementary offer to the existing production ecosystem and to green-field approach
• Preservation of the autonomy of the Intellectual Property
• Complete adaptation of the dedicated building design to the specific partner’s process and products
• Flexible and scalable
• 20.000m² available piece of land
• De-risked approach vs. green-field construction

PARTNERSHIP WITH MAAT PHARMA

• Skyepharma and MaaT Pharma have entered in February 2022 a partnership to establish in the SkyeHub the first exclusive microbiome ecosystem therapies cGMP manufacturing facility in France